Minimum alveolar concentration: ongoing relevance and clinical utility by Aranake, A. et al.
Review Article
Minimum alveolar concentration: ongoing relevance and clinical
utility
A. Aranake,1 G.A. Mashour2 and M.S. Avidan3
1 Medical Student, 3 Professor of Anaesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA
2 Assistant Professor of Anaesthesiology, University of Michigan Medical School, Ann Arbor, Michigan, USA
Summary
Since its introduction in 1965, minimum alveolar concentration (MAC) has served as the standard measure of
potency for volatile anaesthetic agents. It is deﬁned as the minimum alveolar concentration of inhaled anaesthetic at
which 50% of people do not move in response to a noxious stimulus. Within the last 20 years, it has been discovered
that volatile anaesthetics inhibit mobility largely through action on the spinal cord, whereas the amnesic and hyp-
notic effects are mediated by the brain. Studies suggest that the concentration of volatile anaesthetic needed to pre-
vent explicit memory from developing, and to produce unconsciousness, is usually substantially lower than the
concentration required to prevent movement in response to surgery. This review highlights the contributions and
limitations of MAC and its derivatives as metrics of anaesthetic potency with respect to particular behavioural out-
comes. Recent evidence is presented suggesting that a protocol that alerts anaesthetists whenever MAC falls to < 0.5
or 0.7 has the potential to decrease intra-operative awareness with explicit recall, possibly to a similar extent as does
a protocol based on processed electroencephalography-driven alerting.
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For more than 165 years, inhaled volatile anaesthetics
have played a central role in anaesthetic practice [1].
They are relatively inexpensive, convenient to use, and
have predictable therapeutic and side-effects. Today,
measurement of end-tidal anaesthetic concentrations
provides real-time feedback, and facilitates target-
controlled titration of volatile anaesthetic agent
administration.
Between the 1840s and the 1960s, the introduction
of new agents underscored the need for methods to
measure and compare anaesthetic potencies and to
determine adequacy of dosing [1]. Early methods
proposed to assess depth of anaesthesia were based on
clinical observations. Guedel deﬁned stages of anaes-
thesia based on alterations in breathing, muscle tone,
pupil diameter, lacrimation and eyelid reﬂex [2].
In Woodbridge’s concept of ‘nothria’ (a term intended
to encompass mental and motor inactivity coupled
with insensibility) depth of anaesthesia was assessed
clinically according to changes in sensation, move-
ment, reﬂexes and mentation [3]. However, these qual-
itative assessments varied with different anaesthetics,
limiting their clinical utility. In 1965, Eger et al. intro-
duced the concept of minimum alveolar concentration
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(MAC), relating concentration or partial pressure of
inhaled anaesthetics to a single clinically relevant end-
point of general anaesthesia: immobility in response to
a surgical stimulus [4].
The utility and reliability of MAC as an anaes-
thetic metric assumes that the end-tidal anaesthetic
partial pressure is an accurate reﬂection of alveolar
partial pressure, which in turn reﬂects partial pressure
at the effect site. Pharmacokinetic studies report that
partial pressures do indeed equilibrate in the alveoli,
arteries, brain and other tissues at varying rates,
depending on the physical properties of the particular
volatile anaesthetic agent [5, 6]. By determining the
relationship of measured anaesthetic partial pressures
to a given anaesthetic effect, speciﬁcally the suppres-
sion of movement in response to a surgical stimulus,
Eger et al. created a measure of potency. Unlike the
earlier qualitative methods proposed by Guedel and
Woodbridge to assess anaesthetic potency, MAC is
quantitative and can be applied to all inhaled anaes-
thetics [4, 7]. Early studies demonstrated that MAC
was a useful and reproducible metric in both animals
and humans, and that MAC did not increase with
stimulus intensity beyond a certain point (supramaxi-
mal stimulation) [4]. Given these important character-
istics and the ease of measurement of end-tidal
anaesthetic agents, MAC remains the standard index
for comparison of volatile anaesthetic potency.
Although volatile anaesthetics bind to protein tar-
gets [8], the Meyer-Overton relationship, that volatile
anaesthetic potency varies directly with lipid solubility
[9, 10], holds true for commonly used inhaled anaes-
thetic agents [11, 12]. Therefore, MAC can be esti-
mated from the following equation [13]:
MAC  k  1:82 atmospheres
where k = olive oil/gas partition coefﬁcient. Expressed
more simply, the product of MAC and lipid solubility
is a constant; as lipid solubility decreases, MAC
increases (Fig. 1). Thus, if a new volatile anaesthetic
was introduced with a MAC of 9%, we could conclude
that it was less potent (given its higher MAC) and less
soluble than desﬂurane (which has a MAC of 6%).
Minimum alveolar concentration for various
inhaled anaesthetics and factors that inﬂuence MAC
have been identiﬁed [14]. Equipotent administration of
different agents (i.e. expressed as MAC equivalents)
has enabled comparison of pharmacological effects on
physiological variables to be described, such as respira-
tory rate and blood pressure. In this review, we sum-
marise the current literature regarding MAC, examine
factors that modulate MAC, discuss advantages and
disadvantages of its use as a metric, and highlight key
clinical studies that attest to its utility.
Definition of MAC
Minimum alveolar concentration is deﬁned as the
minimum alveolar concentration at sea level of inhaled
anaesthetic required to prevent apparently purposeful
movement in 50% of patients in response to surgical
incision [4, 14]. Synonyms for MAC include ‘EC50 for
immobility’, ‘MAC-movement’, ‘minimum alveolar
partial pressure (for 50% immobility)’ and ‘median
alveolar concentration (for immobility)’. In typical
human studies to determine MAC, anaesthesia is
induced (in a volunteer) with the inhaled agent of
interest and maintained at a preselected end-tidal
anaesthetic concentration (ETAC) for 15 min to allow
equilibration of alveolar and arterial partial pressures.
A standard noxious stimulus is then applied and the
volunteer is observed for an apparently purposeful
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Figure 1 Relationship between MAC (log scale) and
olive oil to gas partition coefﬁcient (k; log scale) [91].
The ﬁgure illustrates that for commonly used inhaled
anaesthetic agents, the product of MAC and k is a
constant. In general, decreased solubility is associated
with decreased potency, increased MAC and faster
onset of action.
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response, such as head or limb movement [4, 15].
These steady-state concentrations may be increased or
decreased based on the observed response. Plotting the
proportion/percentage of patients not moving (depen-
dent variable) against anaesthetic concentrations (inde-
pendent variable) creates a dose-response curve [4,
15]. MAC is a single point on this curve, correspond-
ing to the concentration of anaesthetic at which 50%
of patients do not move in response to the stimulus
(Fig. 2). The standard deviation (SD) of MAC is gen-
erally ~10%, indicating that 1.2 MAC (i.e. MAC + 2
SD) should produce immobility to stimulation in
~95% of patients [16]. The steepness of this curve
reﬂects that there is relatively little variability in the
concentration of inhaled anaesthetic agent required to
prevent movement to a noxious stimulus between sub-
jects. This relatively narrow range of volatile anaes-
thetic concentrations highlights the clinical utility of
these drugs. Compared with potent volatile anaesthetic
agents, there is wider interpatient percentage variability
in the concentration of propofol required to prevent
movement in response to a noxious stimulus [17].
Therefore, notwithstanding other information, practi-
tioners can better predict the concentration at which
the majority of patients are very unlikely to move in
response to noxious stimulus during volatile-based
anaesthesia compared with propofol-based intravenous
anaesthesia [16]. However, the steepness of the slope
for volatile agents also means that a large proportion
of patients could start moving in response to noxious
stimulation with relatively small decrements in anaes-
thetic concentration just below MAC (Fig. 2). This can
occur rapidly and cause adverse consequences with
more insoluble volatile anaesthetics such as desﬂurane
if, for example, the vaporiser is turned off and the
practitioner forgets to restart anaesthetic delivery, or if
the vaporiser becomes empty unnoticed or if the prac-
titioner intentionally turns off the vaporiser before
reversing neuromuscular blockade.
MAC derivatives
A similar approach to the one described to ascertain
MAC has been used to determine the potency of
inhaled anaesthetics for other desirable clinical end-
points of general anaesthesia, such as unconsciousness
(usually inferred from the surrogate of unresponsive-
ness) or amnesia.
In an effort to develop a standard expression for
the anaesthetic concentration at which consciousness
might be regained, Stoelting et al. introduced the con-
cept of ‘MAC-awake’. An appropriate voluntary
response (e.g. eye-opening) to verbal command was
considered a positive response that indicated the pres-
ence of consciousness; MAC-awake was then deﬁned
as the anaesthetic concentration needed to suppress a
voluntary response to verbal command in 50% of
patients [18]. It was determined by averaging anaes-
thetic concentrations in research participants that just
permitted and that just prevented a positive response
during recovery from general anaesthesia. While the
ratio of MAC-awake to MAC varies considerably
across different volatile agents, it is comparable for the
commonly used volatile anaesthetics isoﬂurane, sevo-
ﬂurane and desﬂurane (Table 1). Clinically, the ratio
describes emergence from anaesthesia; a ratio closer to
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Figure 2 Relationship between anaesthetic concentra-
tion and the percent of people not moving in response
to a surgical stimulus [4]. This ﬁgure illustrates the rel-
atively narrow interperson variability in the anaesthetic
concentration required to suppress movement. Factors
that shift the curve to the left (i.e. decrease MAC) and
to the right (i.e. increase MAC) are shown in the
arrows [14]. Population effective concentrations are
shown for 5% (EC5), 50% (EC50) and 95% (EC95) of
the population [16]. The EC50 is synonymous with
MAC. SD, standard deviation.
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1 signiﬁes patients will recover responsiveness sooner,
i.e. at relatively higher anaesthetic concentrations or
MAC equivalents (e.g. ~ 0.5 MAC for halothane vs
~ 0.3 MAC for desﬂurane). Yet, despite its use as a
surrogate, ‘unresponsiveness’ does not always indicate
‘unconsciousness’. Furthermore, MAC-awake studies
have been conducted with volunteers who were not
exposed to noxious stimuli. Therefore, anaesthetic con-
centrations at MAC-awake during surgical stimulation
do not necessarily imply that 50% of patients are
unconscious; they may only be unresponsive in the
absence of noxious stimulation.
Amnesia is also a clinically important effect of
general anaesthetics. Memory can be divided into
explicit (conscious) and implicit (unconscious) recall,
with explicit recall being further subdivided into epi-
sodic (memory of events) and semantic (memory of
facts about the world). The primary goal of anaesthe-
tists regarding memory is to suppress explicit episodic
memory of surgical or procedural events, which is the
form of peri-operative memory that has been associ-
ated with post-traumatic stress disorder [19]. Although
less-well studied, the anaesthetic concentration
required to suppress recollection of a noxious stimulus
in 50% of patients (MAC-amnesia), is theoretically
important both to the patients and the practitioners.
Studies have demonstrated that the alveolar concentra-
tion of volatile anaesthetics at which amnesia is
achieved is lower than MAC; however, there is proba-
bly more interpatient variability for MAC-amnesia [20,
21]. Human and animal studies suggest that the con-
centration required to prevent explicit recall varies sub-
stantially among volatile anaesthetic agents. A rodent
study demonstrated that the amnesic potency differed
signiﬁcantly for ﬁve inhalational anaesthetics, ranging
from 0.06 MAC to 0.3 MAC [21]. Amnesic potency
followed the Meyer-Overton relationship; nitrous oxide
was the most potent amnesic agent relative to its MAC
and halothane was the least potent amnesic agent rela-
tive to its MAC [21]. Interestingly, this result was not
replicated by a human study in which nitrous oxide
was found to be far less potent at suppressing memory
than isoﬂurane [22]. Anaesthetics are therapeutically
useful because at sub-hypnotic doses, both volatile and
intravenous agents often prevent consolidation of epi-
sodic memories [21, 23]. Even if patients are occasion-
ally aware and have untoward experiences during
surgery, it is possible that they will not remember
these experiences at anaesthetic concentrations exceed-
ing MAC-amnesia. Whether or not it is ethically
acceptable for patients to experience intra-operative
distress, without explicitly remembering the experience
postoperatively, is a subject of heated debate [24–26].
Importantly, the concentration required to prevent
recall of painful stimulation may be considerably
higher than that required for the verbal stimulus often
used in studies investigating amnesic potency [22, 27].
Another derivative of MAC is the minimum alveo-
lar concentration of volatile anaesthetic that blocks
autonomic responses to surgical incision in 50% of
patients (MAC-BAR) [28]. The autonomic responses
commonly used to deﬁne MAC-BAR are changes in
pupil dilation, heart rate and blood pressure. Autonomic
blockade can be accomplished to varying extents; MAC-
BAR is therefore an estimate at best. Various other
MAC measures, such as MAC for tracheal stimulation
or reﬂex pupillary dilatation, have also been explored
[29, 30], but have the same limitations as MAC-BAR in
relation to precision of the outcome measure.
We return to the discussion of MAC-awake to
illustrate an important point regarding the neurobiol-
ogy of anaesthetic induction and emergence. It is often
assumed that the measure of MAC-awake reﬂects the
MAC at which one both loses and regains conscious-
ness. However, this assumption is not necessarily
valid. MAC-awake is the alveolar concentration of vol-
atile anaesthetic at which 50% of patients remain
unresponsive to verbal commands when anaesthetic
concentration the decreased (the emergence pathway).
MAC-unawake would then be the alveolar concentra-
tion of volatile anaesthetic at which 50% of patients
Table 1 Minimum alveolar concentration (MAC) and
MAC-awake values for commonly used inhaled anaes-
thetic agents for 40-year-old humans.
Agents MAC* MAC-awake*
MAC-awake/
MAC
Halothane 0.76 0.41 0.55
Isoflurane 1.15 0.49 0.38
Sevoflurane 2 0.62 0.34
Desflurane 6 2.5 0.34
Nitrous oxide 105 68 0.64
*values expressed as percentage at 1 atmosphere.
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remain responsive to verbal commands when anaes-
thetic concentration is increased (the induction path-
way). Anecdotal experience with patients, theoretical
models and compelling murine and fruitﬂy data sug-
gest that these processes might not be mirror images;
there is an observed hysteresis between the induction
and emergence pathways [31] (Fig. 3). The concentra-
tion of anaesthetic required to achieve unresponsive-
ness or immobility at induction is often much higher
(e.g. two to three times) than the concentration of
anaesthetic at which the mice or fruitﬂies start to
respond or move at emergence [31]. The path-depen-
dent dose-response curves also illustrate greater vari-
ability in responsiveness to anaesthetic concentration
for emergence than for induction. Thus, anaesthetic
concentration predicts loss of responsiveness much
more reliably than recovery of responsiveness.
Although conceived independently, the concept of
‘neural inertia’ bears relevance to the interpretation of
MAC. Neural inertia has been deﬁned as an intrinsic
resistance to state transitions such as the induction of
or emergence from general anaesthesia. It is now clear
that the neurobiological substrates of these two pro-
cesses are distinct and, as mentioned previously, that
the hysteresis between ‘going under’ and ‘coming out
of’ anaesthesia is not simply a matter of pharmaco-
kinetics. Thus, the anaesthetic concentration at which
consciousness is lost in humans (MAC-unawake) is
likely to be higher than the anaesthetic concentration
at which they will regain consciousness (MAC-awake).
From a practical standpoint, a gap between MAC-
unawake and MAC-awake in anaesthetised patients
could provide a safety cushion. When anaesthetic con-
centration falls slightly below the concentration at
which induction occurred, the majority of patients
might remain unaware and unresponsive. On the other
hand, patients who had collapse of the hysteresis
referred to previously (i.e. MAC-awake and MAC-
unawake converge) or those who are resistant to the
amnesic actions of anaesthetic agents could be at
increased risk for intra-operative awareness with post-
operative explicit recall. It is also possible that intense
noxious stimulation could shift the MAC-awake and
MAC-amnesia curves such that wakefulness and mem-
ory consolidation could occur at higher than expected
concentrations of volatile anaesthetic agents. This em-
phasises the theoretical importance of trying to mini-
mise noxious stimuli during general anaesthesia with
appropriate supplementary analgesic strategies (e.g.
regional anaesthetic techniques, multimodal
analgesics).
Neurobiology of MAC
Motivated by the concept of MAC, investigators prob-
ing inhaled anaesthetic mechanisms sought to deter-
mine how these agents might produce immobility [32].
The lack of an obvious association between cortical
electrical activity (e.g. measured by electroencephalog-
raphy-based monitoring) and immobility to noxious
stimuli suggested that inhaled anaesthetics might
suppress movement by action at sites other than the
cortex alone [33]. Studies suggested that immobility, as
measured by MAC, is mediated by the action of
inhaled anaesthetics on the spinal cord [34–37]. Sev-
eral in-vivo studies in goats demonstrated that, when
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Figure 3 Relationship between isoﬂurane concentra-
tion and absence of righting reﬂex during induction of
and emergence from anaesthesia in wild-type mice.
This ﬁgure, which was modiﬁed from a ﬁgure by
Friedman et al. [31], shows that there is a hysteresis
between the induction and emergence pathways in
wild-type mice. During induction of anaesthesia, a
higher isoﬂurane concentration is required to achieve
loss of the righting reﬂex than the isoﬂurane concen-
tration at which the righting reﬂex returns during
emergence from anaesthesia. Effective concentration 50
(EC50) on the induction path corresponds to the con-
centration at which 50% of mice lose the righting
reﬂex. Effective concentration 50 (EC50) on the emer-
gence path corresponds to the concentration at which
50% of mice regain the righting reﬂex.
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preferentially delivered to the brain, the partial pres-
sure of anaesthetic agent required to suppress move-
ment was greater than when delivered to the whole
body. Separating perfusion of the spinal cord and
brain, and delivering anaesthetic agent preferentially to
the brain, increased MAC for isoﬂurane from 1.2% to
2.9% [34]. An analogous study demonstrated a similar
increase in MAC for halothane from 0.9% to 3.4%
[35]. This increase in MAC with preferential delivery
of volatile anaesthetic agent to the brain suggested an
alternative primary site of action for volatile anaes-
thetic-induced immobility. Complementary studies in
rats introduced lesions in the central nervous system
(CNS) to sever connections between the spinal cord
and the brain, such as precollicular decerebration and
spinal cord transection at the thoracic level; neither of
these lesions altered MAC [36, 37]. The lack of move-
ment in these rats was produced by inhaled anaesthetic
concentrations similar to controls, suggesting that the
primary site of action is the spinal cord [36, 37]. Evi-
dence suggests that anaesthetics suppress both sensory
processing of noxious stimuli and motor-neuron reﬂex
responses to prevent movement [38, 39]. Both animal
and human studies have found that volatile anaesthet-
ics depress spinal motor-neuron excitability, which is a
possible mechanism by which they suppress movement
in the setting of noxious stimuli [40, 41].
While the spinal cord largely mediates anaesthetic-
mediated immobility, the actions of these agents in
subcortical and cortical brain regions mediate amnesia
and hypnosis. A study of healthy volunteers receiving
sub-MAC concentrations of isoﬂurane found suppres-
sion of learning and memory at concentrations lower
than those suppressing responsiveness and movement
[23]. Studies of animals and humans have identiﬁed
regions of the brain, such as the amygdala, hippocam-
pus and cortex, that contribute to the formation of
explicit episodic memory and may be targets for the
amnesic effects of inhaled anaesthetics [42, 43].
Inhaled anaesthetics produce hypnosis by suppressing
both arousal and subjective experience. Actions on
subcortical structures, which modulate sleep-wake
cycles, probably mediate effects on arousal. The actions
of inhaled anaesthetics on thalamocortical and
corticocortical networks are thought to inhibit subjec-
tive experience.
Factors that affect MAC
Many factors alter MAC, thereby increasing or
decreasing the anaesthetic concentration required to
prevent movement (Fig. 2). When a factor is present
that increases MAC in an individual, volatile anaes-
thetics have decreased potency for that person. Thus,
in the presence of these factors, patients will require a
higher concentration of the volatile agent. Conversely,
for factors that decrease MAC, the volatile anaesthetic
agents have increased potency. In the presence of these
factors, patients require a lower concentration of the
volatile agent. It is important to qualify that factors
that alter MAC might not similarly impact other MAC
measures, such as MAC-awake, MAC-unawake, MAC-
amnesia and MAC-BAR.
Physiological factors
Many physiological factors have been associated with
alterations in MAC. For example, the concentration of
anaesthetic agent required to suppress movement var-
ies inversely with the age of an individual. Human
studies have determined that MAC peaks at 6 months
of age [44], after which it progressively decreases [45,
46]. A comprehensive meta-analysis determined the
relationship between MAC and age could be described
with reasonable accuracy by the following equation:
MACage = MAC40 9 10
0.00269(age  40)
where MACage is the MAC at a given age and MAC40
is the MAC value at age 40 [46, 47]. Using this equa-
tion, charts outlining equipotent concentrations of vol-
atile anaesthetics adjusted for age and concurrent
nitrous oxide use have been developed to guide clinical
practice (Fig. 4) [47]. Variations in body temperature
have also been associated with differences in anaes-
thetic requirements. Studies in various animal models
have demonstrated a positive linear relationship
between temperature and anaesthetic requirement [48–
50]. A murine model demonstrated that, for body tem-
peratures of 32–37 °C, a decrease by 1 °C resulted in
a 5% decrease in MAC for isoﬂurane [50]. The effect
of temperature on MAC is hypothesised to be attributable
to effects of temperature changes on cerebral oxygen con-
sumption [51]. Elevations or reductions in serum sodium
coinciding with changes in sodium concentration and
osmolality in cerebrospinal ﬂuid may alter anaesthetic
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requirements. Hypernatraemia is associated with an
increase in MAC, while hyponatraemia is associated
with a decrease in MAC [52]. Several other physiologi-
cal derangements, such as anaemia, hypercarbia and
hypoxia, have also been shown to decrease MAC [53,
54]. The potency of inhaled anaesthetics is greater in
women during pregnancy and in the early postpartum
period, resulting in a decrease in MAC [55].
Preliminary studies have provided evidence for
other factors that may affect MAC, notably genetic
background [56, 57]. Small studies in mice and humans
have suggested that mutations in the melanocortin-1
receptor (MCR-1) gene are associated with increased
requirements for volatile anaesthetic agents, or
increased MAC [58, 59]. Obesity has also been explored
as a modiﬁer of MAC, but a recent animal study mod-
elling human metabolic syndrome demonstrated no dif-
ference in MAC compared with non-obese controls
[60]. Consistent with other investigations, this study
also supported genetic background, but not biological
sex, as an important determinant of MAC.
Pharmacological factors
Drugs administered in the peri-operative setting often
increase the potency of inhalational anaesthetic agents.
For example, sedative-hypnotic agents, such as benzo-
diazepines and barbiturates, decrease MAC [61–64].
Midazolam premedication results in dose-dependent
reductions in MAC [65]. Similar to benzodiazepines,
other commonly used intravenous drugs that potentiate
or activate GABAA, including propofol, also decrease
MAC [66]. Evidence suggests that non-GABAergic
drugs such as ketamine and a2-adrenergic agonists
decrease MAC [67, 68]. Numerous studies have demon-
strated reductions in MAC with the use of opioid anal-
gesics [69]. Again, it is important to emphasise that
these drugs might all alter MAC, but not similarly affect
other MAC derivatives. For example, through their
nociceptive actions, potent opioid analgesics might help
to prevent movement in response to surgical stimula-
tion, but might not as profoundly decrease the concen-
tration of volatile anaesthetic required to achieve
amnesia.
In addition to peri-operative anaesthetic and anal-
gesic agents, acute or chronic use of various medica-
tions and substances of abuse also alter inhalational
anaesthetic requirements. For example, drugs that
increase catecholamine release in the CNS, such as
cocaine, increase MAC during acute intoxication [70].
Canine studies demonstrated a dose-dependent
increase of MAC for halothane following acute cocaine
administration [71]. In contrast, chronic cocaine expo-
sure is associated with a decrease in MAC for isoﬂura-
ne [72]. Similar results have been demonstrated with
acute and chronic amfetamine exposure; MAC
increased in a dose-dependent manner with acute use
and decreased with chronic use [73, 74]. Conversely,
the results of several studies suggest that chronic etha-
nol use increases MAC, while acute ethanol adminis-
tration decreases MAC [75–77].
Pathological factors
In general, patients presenting with a depressed level
of consciousness due to trauma or cerebrovascular
insult have decreased anaesthetic requirements. Patho-
logical changes associated with dementia or other
neuro-degenerative changes may also affect anaesthetic
Figure 4 Age-adjusted iso-minimum alveolar concen-
tration (iso-MAC) lines for desﬂurane. This is modi-
ﬁed from a ﬁgure by Nickalls and Mapelson [47],
which shows the effect of increasing age on the con-
centration (percentage at sea level) of desﬂurane
required to achieve escalating MAC equivalents from
0.6 MAC to 1.6 MAC. Similar charts for all commonly
used inhaled agents have been produced by Nickalls
and Mapelson [47].
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requirements. A murine model of Alzheimer’s disease
demonstrated that the neuropathology associated with
Alzheimer’s disease confers a resistance to the
hypnotic actions of inhaled anaesthetics [78, 79].
Advantages and limitations of MAC and
MAC derivatives
Several studies before the introduction of MAC
suggested that alveolar partial pressures would mirror
brain partial pressures after a sufﬁcient period of time.
By combining the pharmacokinetics of inhaled anaes-
thetics with an important categorical response – move-
ment – Eger et al. created a novel index of anaesthetic
potency. As a dosing metric of anaesthesia, MAC has
several advantages. Early studies demonstrated a small
inter-individual variance in MAC. That is, for a given
stimulus, the anaesthetic concentration required to pre-
vent movement is similar from person to person. End-
tidal concentrations are easy to measure in clinical
practice and administered anaesthetic concentration rel-
ative to MAC can be tracked in real time. The caveat is
that there are equilibration delays for all volatile anaes-
thetics (especially the more soluble vapours like halo-
thane and isoﬂurane) between end-tidal levels and
effect-site concentration. In contrast to previously pro-
posed metrics of anaesthetic depth, MAC applies simi-
larly to all inhaled anaesthetics and thus allows for
ready comparison of potency. The ability to quantify
MAC for various volatile anaesthetics allowed practitio-
ners to compare and contrast side-effects with speciﬁc
anaesthetics at MAC equivalent multiples (e.g. ½ MAC,
MAC and 2 MAC). Equipotent concentrations of each
agent inﬂuence organ systems including cardio-
vascular, respiratory and neuromuscular to differing
degrees. The quantitative comparisons of these side-
effects (e.g. effects on airway reactivity, blood pressure
and heart rate) help to inform the choice of inhaled
anaesthetic in clinical practice. Furthermore, the concept
of MAC has aided investigation of factors that alter
anaesthetic requirements and helped guide investigation
into the mechanisms of action of inhaled anaesthetics.
Minimum alveolar concentration is a useful con-
struct that has advanced clinical care and scientiﬁc
investigation. However, it does have limitations. For
example, MAC is not a reliable indicator of hypnosis
or unconsciousness. The comparable metric for con-
sciousness, MAC-awake, is also unreliable due to the
behavioural component of the response. Anaesthetic
concentrations that suppress goal-directed motor
response to verbal stimuli do not necessarily produce
unconsciousness, highlighting the distinction between
responsiveness and consciousness. A recent review of
studies using the isolated forearm technique (IFT), a
method which spares one hand from the effects of
neuromuscular blockers, reported that a median of
37% of patients demonstrated goal-directed responsive-
ness to verbal stimulation during general anaesthesia
[26]. Of interest, spontaneous movement of the spared
hand was rare (if not absent) in these patients, includ-
ing those who reported pain. It is not known why a
behavioural response was elicited by a verbal stimulus
but not by the experience of noxious stimulus. These
and other data that dissociate responsiveness and con-
sciousness [26, 80] suggest that MAC – a measure of
responsiveness – may not necessarily be informative
regarding the state of consciousness. However, because
loss of motor responsiveness occurs at a higher dose
than loss of ‘consciousness’, MAC is a very good prag-
matic end-point as it gives the anaesthetist reasonable
conﬁdence that the patient is likely to be unconscious.
One of the most notable limitations of MAC is
that it is not directly applicable to the administration
of total intravenous anaesthesia. Furthermore, modern
peri-operative management incorporates various types
of drugs, complicating the interpretation of MAC. The
use of neuromuscular blockade to produce paralysis
renders the concentration of inhaled anaesthetic
required to suppress movement uninformative. While
these drugs tend to decrease MAC they may not affect
MAC-awake or MAC-amnesia in a parallel manner.
Given that multimodal or balanced anaesthetic tech-
niques (e.g. potent inhaled agent plus neuromuscular
blocking drug plus opioid analgesic plus intravenous
hypnotic agent) are commonly used, the utility of
MAC as a ‘pure’ measure of anaesthetic effect is mark-
edly curtailed.
MAC and clinical outcomes
Concentrations of inhaled anaesthetics, measured in
MAC equivalents, have been used to study several
clinical outcomes in surgical patients, such as intra-
operative awareness with explicit recall (AWR) and
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postoperative mortality. The former is a rare but
feared complication of (inadequate) general anaesthesia
associated with devastating psychological sequelae [81,
82]. Efforts to prevent AWR events have focused on
attaining adequate depth of anaesthesia by adjustment
of anaesthetic dosing in response to MAC or electro-
encephalographic measures. Several large randomised
controlled trials compared protocols based on MAC
and bispectral index (BIS) values in the prevention of
AWR. In studies of patients at high risk for AWR,
both protocols reduced the incidence of AWR from
incidence rates previously reported in high-risk
patients [83, 84]. The Michigan Awareness Control
Study, a randomised comparative effectiveness trial
conducted in more than 21 000 patients, was not able
to detect a difference between MAC- and BIS-guided
protocols [85]. Thus, across a wide spectrum of risk
levels, MAC-based protocols may be useful in prevent-
ing AWR.
In a retrospective review of intra-operative data,
the combination of concurrent low end-tidal levels
(< 0.7 MAC) and low blood pressure (mean arterial
pressure < 75 mmHg) and low bispectral index values
(BIS < 40) was associated with an approximately four-
fold increase in postoperative mortality [86]. It is not
clear from this study whether the association with mor-
tality of concurrent low end-tidal values, low BIS and
low blood pressures (termed ‘triple low’ by the investi-
gators) is causal or epiphenomenal [87]. Currently,
there is no evidence to suggest that, within a clinically
relevant range, volatile anaesthetic agents promote
adverse outcomes [88]. Further studies are needed to
clarify whether, based on concentration or patient vul-
nerability, volatile anaesthetics have the potential to
increase serious morbidity or mortality unrelated to
their cardiorespiratory side-effects. For example, there
are studies that suggest that exposure to higher anaes-
thetic concentrations might increase the likelihood of
postoperative delirium and cognitive decline [89, 90].
Conclusion
Despite its limitations, It remains the most commonly
used measure of anaesthetic potency for inhaled drugs.
It has withstood the test of time and prevails as the
routine metric of anaesthetic depth almost 50 years
since its description. Volatile-based general anaesthesia
is the most common technique in both highly resour-
ced and under-resourced care environments. Measure-
ment of volatile anaesthetic concentration in real time
is reliable, inexpensive and available around the world.
Given its relatively narrow interpatient variability,
MAC is a pragmatic surrogate for a meaningful anaes-
thetic end-point – absence of patient movement in
response to surgical stimulation. Future candidate
measures of anaesthetic depth will have to prove their
superiority to MAC.
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